市場調査レポート
商品コード
1495406
固形臓器移植の拒絶反応市場:提供品目別、臓器タイプ別、拒絶反応タイプ別、エンドユーザー別-2024-2030年の世界予測Solid Organ Transplantation Rejection Market by Offering (Diagnosis & Testing Solutions, Medications), Organ Type (Heart, Kidneys, Liver), Rejection Type, End-User - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
固形臓器移植の拒絶反応市場:提供品目別、臓器タイプ別、拒絶反応タイプ別、エンドユーザー別-2024-2030年の世界予測 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
|
固形臓器移植の拒絶反応市場規模は、2023年に77億9,000万米ドルと推定され、2024年には81億5,000万米ドルに達し、CAGR 4.90%で2030年には108億9,000万米ドルに達すると予測されます。
固形臓器移植は、肺、心臓、腎臓、肝臓などの重要な臓器の置換を含み、患者の生存率と生活の質を著しく向上させる。固形臓器移植の拒絶反応は、レシピエントの免疫系が移植臓器を異物と認識し、移植臓器にダメージを与えるプロセスであり、固形臓器移植の拒絶反応による薬物療法や治療が必要となります。慢性疾患、加齢、生活習慣などが主な原因で、臓器不全に苦しむ人の数は世界的に増加しています。臓器移植の需要が増加するにつれて、効果的な拒絶反応管理ソリューションへの要求も高まっています。このような臓器移植の増加は、市場の成長を促進します。さらに、固形臓器移植の進歩や拒絶反応管理技術の向上に対する一般市民や専門家の意識の高まりも、市場成長に大きく寄与しています。しかし、固形臓器移植には、移植前のスクリーニング、手術そのもの、術後のケア、継続的な免疫抑制治療など、複雑で費用のかかる医療処置が含まれるため、高額な費用が必要となり、特に経済的に発展していない地域では、患者にとって移植へのアクセスが制限され、ヘルスケア予算が圧迫される可能性があるため、市場成長の大きな障壁となり得る。現在進行中の改良型免疫抑制治療法の開拓は、移植後の臓器拒絶反応の発生率を低下させることにより、市場拡大の機会を提供するものです。
主な市場の統計 | |
---|---|
基準年[2023] | 77億9,000万米ドル |
予測年[2024] | 81億5,000万米ドル |
予測年 [2030] | 108億9,000万米ドル |
CAGR(%) | 4.90% |
地域別の洞察
南北アメリカ、特に米国では、高度な医療施設と整備されたヘルスケアシステムにより、臓器移植の普及率が高いです。この地域は強固な臓器移植ネットワークを有し、相当数の移植手術が行われているため、抗拒絶反応薬や治療薬に対するニーズが高いです。これらの製品は、移植臓器に対する免疫反応を抑えるために不可欠です。米国はまた、規制当局の強力なサポートと多額のヘルスケア支出により、新しい先進的な治療法の採用でリードしています。アジア太平洋地域は、固形臓器移植拒絶反応市場の成長を示しています。これは、ヘルスケア・インフラの増加、治療費の低下による医療ツーリズムの増加、慢性疾患に対する有効な選択肢としての移植に対する意識の高まりに後押しされています。インドや中国を含む国々では、移植件数が増加しています。EMEA地域の固形臓器移植拒絶反応介入市場は、臓器移植手術の増加と移植拒絶反応に対する意識の高まりにより、著しい成長を示しています。欧州には確立されたヘルスケアシステムがあり、規制の枠組みも整っています。中東およびアフリカは、ヘルスケアインフラの改善や移植プログラムの国際的な協力関係の影響を受け、緩やかな成長を遂げています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、固形臓器移植の拒絶反応市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、ビジネス戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、固形臓器移植の拒絶反応市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、固形臓器移植の拒絶反応市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[181 Pages Report] The Solid Organ Transplantation Rejection Market size was estimated at USD 7.79 billion in 2023 and expected to reach USD 8.15 billion in 2024, at a CAGR 4.90% to reach USD 10.89 billion by 2030.
Solid organ transplantation, encompassing the replacement of vital organs, including the lungs, heart, kidneys, or liver, markedly improves patient survival and quality of life. Solid organ transplantation rejection is a process in which a recipient's immune system identifies the transplanted organ as foreign and causes damage to the transplanted organ, creating the need for solid organ transplantation rejection medications and therapies. There is a rising number of individuals worldwide who suffer from organ failures, primarily due to chronic diseases, aging, and lifestyle factors. As the demand for organ transplants increases, the requirement for effective rejection management solutions also increases. This rise in organ transplantation propels the market growth. In addition, the rising public and professional awareness of advancements in solid organ transplantation and improved rejection management techniques significantly contribute to market growth. However, solid organ transplantation involves complex and costly medical procedures, including pre-transplant screenings, the surgery itself, post-operative care, and ongoing immunosuppression treatments, which require high costs and can be a significant barrier to market growth, as they may limit transplantation's accessibility for patients and strain healthcare budgets, particularly in less economically developed regions. The ongoing development of refined immunosuppressive treatments offers the opportunity for market expansion by reducing the incidence of organ rejection post-transplant.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 7.79 billion |
Estimated Year [2024] | USD 8.15 billion |
Forecast Year [2030] | USD 10.89 billion |
CAGR (%) | 4.90% |
Regional Insights
In the Americas, particularly the United States, there is a high prevalence of organ transplants due to advanced medical facilities and a well-structured healthcare system. This region has a robust organ transplantation network and showcases a significant number of transplant procedures, leading to a substantial need for anti-rejection drugs and therapies. These products are essential to help in reducing the immune response against transplanted organs. The U.S. also leads in adopting new and advanced therapies due to strong regulatory support and substantial healthcare spending. The Asia-Pacific region is showcasing growth in the solid organ transplant rejection market, propelled by increasing healthcare infrastructure, rising medical tourism due to lower treatment costs, and growing awareness about transplantation as a viable option for chronic diseases. Countries, including India and China are seeing increased numbers of transplantations. The market for solid organ transplant rejection interventions in the EMEA region showcases significant growth due to increasing organ transplant procedures and heightened awareness about transplant rejection. Europe has well-established healthcare systems and supportive regulatory frameworks. The Middle East and Africa are witnessing gradual growth, influenced by improving healthcare infrastructure and international collaborations for transplant programs.
Market Insights
The market dynamics represent an ever-changing landscape of the Solid Organ Transplantation Rejection Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Solid Organ Transplantation Rejection Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Solid Organ Transplantation Rejection Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Pioneering Partnership Targets Breakthrough in Organ Transplant Rejection Prevention
Taiwan Bio and TRACT Therapeutics collaborated on cutting-edge cellular therapy aimed at transforming the prevention of allograft rejection in solid organ transplants. This new alliance enhanced a Phase 2 clinical trial across multiple centers in the U.S. and Taiwan, focusing on decreasing the reliance on immunosuppressant drugs in recipients of kidney transplants from living donors. Combining Taiwan Bio's expertise in cellular therapy manufacturing with TRACT Therapeutics' innovative regulatory T-cell therapy platform, this partnership aims to significantly enhance transplant outcomes while improving patients' quality of life. [Published On: 2023-12-06]
New Development in Post-Transplant Monitoring: Real-Time Electronic Organ Health Tracker
Researchers at Northwestern University innovated the first electronic device designed for continuous, real-time health monitoring of transplanted organs. This study introduces a novel, ultrathin sensor that sits atop transplanted kidneys to monitor for temperature anomalies indicative of inflammation or other complications, which could signal rejection. The device enhances patient safety by wirelessly transmitting data directly to healthcare providers via smartphone or tablet, ensuring immediate medical response to potential issues. [Published On: 2023-09-08]
GenDx Acquires Licensing for cfDNA Assay from Torino University to Enhance Lung Transplant Monitoring
GenDx, a Dutch company, has obtained exclusive licensing rights for a cell-free DNA (cfDNA) assay from Torino University. This innovative diagnostic tool is specifically designed to detect and monitor organ rejection in lung transplant recipients. The cfDNA assay offers a non-invasive method to identify early signs of rejection, which is crucial for the timely intervention and management of transplant patients. This advancement promises to enhance post-transplant care by facilitating continuous monitoring and potentially improving patient outcomes. [Published On: 2023-05-25]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Solid Organ Transplantation Rejection Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Solid Organ Transplantation Rejection Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accord Healthcare Limited, Asahi Kasei Corporation, Astellas Pharma Inc., Biocon, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Eris Lifesciences Ltd., Eurofins Transplant Diagnostics, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Globela Pharma, Lupin Limited, Manus Aktteva Biopharma LLP, Natco Pharma Ltd., Novartis AG, Panacea Biotec Pharma Ltd., Pfizer Inc., Plexision, Sanofi S.A., SAS Alsachim by Shimadzu Group, Strides Pharma Global Pte Ltd., Teva Pharmaceuticals Inc., Thermo Fisher Scientific Inc., Veloxis Pharmaceuticals A/S, and Zydus Lifesciences Limited.
Market Segmentation & Coverage